VOR

19.1903.62%
SM

Sandesh Mahatme

Chief Business Officer & CFO

Mr. Sandesh Mahatme, also known as Sandy, LL.M., is Chief Business Officer & Chief Financial Officer of Vor Biopharma Inc. from July 9, 2025. He is a Director of CRISPR Therapeutics, Inc. since May 2024. Mr. Sandesh is Independent Director of CRISPR Therapeutics AG from May 30, 2024. He Co-Founded and had been its President, Chief Operating Officer, Chief Financial Officer of National Resilience, Inc until June 2024 and had been its Treasurer. He had been a Director of Epirium Bio, Inc. since October 2020 until February 2025. He holds board positions with Idorsia Pharmaceuticals Ltd. since May 2020 and Flexion Therapeutics, Inc. Mr. Mahatme is the President, Chief Operating Officer and CFO of a stealth company backed by ARCH Venture Partners. He served as an Independent Director at Flexion Therapeutics, Inc. from July 22, 2014 to June 2021. He had been Chief Business Officer and Executive Vice President of Sarepta Therapeutics, Inc. from March 2017 to July 10, 2020. Mr. Mahatme had been the Chief Financial Officer of Sarepta Therapeutics, Inc. from November 5, 2012 to July 10, 2020 and served as its Senior Vice President since November 5, 2012 and Chief Accounting Officer since October 4, 2013. Prior to joining Sarepta in 2012, Mr. Mahatme served in various roles including Senior Vice President of Corporate Development, Corporate Treasurer, Head of Tax and Senior Vice President of Tax at Celgene Corporation from January 2006 to November 2012. He served as Senior Vice President of Finance at Celgene. At Celgene, he was instrumental in building its Treasury and Tax functions before establishing the Corporate Development department, focused on strategic, targeted initiatives including emerging markets, acquisitions, licensing, strategic planning and global manufacturing expansion. Prior to Celgene, Mr. Mahatme worked at Pfizer Inc. for eight and a half years in senior roles in Business Development and Corporate Tax From 1997 to 2006. He started his career at Ernst & Young, where he advised multinational corporations on a broad range of transactions. He has been an Independent Director of Elcelyx Therapeutics, Inc. since October 12, 2016. He has been a Non-Executive Director of Idorsia Ltd., since May 13, 2020. He had been a Director of Aeglea Biotherapeutics, Inc. from June 2015 to July 08, 2022. He is a Member of the New York State Bar Association. Mr. Mahatme received Master of Laws (LL.M) degrees from Cornell Law School and NYU School of Law.

公司職務